Doximity Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Doximity verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 39.2%, während die Gewinne der Branche Healthcare Services jährlich um gewachsen und zwar um 8.3%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 27.5%. Die Eigenkapitalrendite von Doximity beträgt 16.4% und die Nettomargen betragen 31%.

Wichtige Informationen

37.2%

Wachstumsrate der Gewinne

23.2%

EPS-Wachstumsrate

Healthcare Services Wachstum der Industrie	1.7%
Wachstumsrate der Einnahmen	20.3%
Eigenkapitalrendite	17.6%
Netto-Marge	32.5%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15

Recent updates

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Sep 23

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Dec 14

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 30

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Sep 25

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Jul 29

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Jul 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Jun 21

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Apr 07

Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Mar 20

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Dec 25

Doximity: On The Right Path To Further Consolidate Market Share

Dec 22

Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Dec 04

Doximity up 16% after fiscal 2023 Q2 beats, FY revenue range includes consensus

Nov 10

Doximity, down 9%, falls below IPO price

Oct 12

Aufschlüsselung der Einnahmen und Ausgaben

Wie Doximity Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NYSE:DOCS Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	494	161	171	83
31 Mar 24	475	148	170	82
31 Dec 23	468	138	169	83
30 Sep 23	448	123	167	84
30 Jun 23	437	119	166	83
31 Mar 23	419	113	160	80
31 Dec 22	402	119	153	76
30 Sep 22	384	141	146	72
30 Jun 22	362	148	138	68
31 Mar 22	344	133	128	62
31 Dec 21	317	107	114	57
30 Sep 21	277	57	101	53
30 Jun 21	243	30	88	47
31 Mar 21	207	22	78	44
31 Dec 20	177	14	67	40
31 Mar 20	116	11	46	32
31 Mar 19	86	1	40	27

Qualität der Erträge: DOCS hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: DOCSDie aktuellen Gewinnspannen (31%) sind höher als im letzten Jahr (26.9%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: DOCSIn den letzten 5 Jahren sind die Einnahmen von 39.2% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: DOCSDas Gewinnwachstum des Unternehmens im letzten Jahr (30.8%) liegt unter seinem 5-Jahres-Durchschnitt (39.2% pro Jahr).

Erträge im Vergleich zur Industrie: DOCS Das Gewinnwachstum im vergangenen Jahr (30.8%) übertraf das der Branche Healthcare Services 8.6% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: DOCSDie Eigenkapitalrendite des Unternehmens (16.4%) wird als niedrig angesehen.

Doximity Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity: Adding Value Using AI But Faces Near-Term Risks

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Insufficient new directors

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 11% to US$26.91

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 13% to US$32.08

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Second Quarter Ending September 30, 2023 and Fiscal Year Ending March 31, 2024

Doximity Earnings: Too Many Problems, Sell

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Doximity, Inc. to Report Q1, 2024 Results on Aug 08, 2023

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Doximity: Continue To See Positive Upside From Current Stock Level

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Doximity: Digital Health Play With Strong Fundamentals

Doximity, Inc., Annual General Meeting, Jul 26, 2023

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $200 million worth of its shares.

Full year 2023 earnings: EPS exceeds analyst expectations